Abstract
Mitochondria are involved in different physiological and pathological processes that are crucial for tumor cell physiology, growth and survival. Since cancer cells have frequently disrupted different cell death pathways that promote their survival, mitochondria may be key organelles to promote cell death in cancer cells. The present review is focused on the different experimental and therapeutic cancer strategies addressed to either target mitochondria directly, or use mitochondria as mediators of apoptosis. While the first group includes drugs that act on glycolysis, β-oxidation, electron transport chain, mitochondrial permeability and the Bcl-2/IAP family protein, the second one consists of those drugs that cause cell death through the intrinsic apoptosis pathway by promoting ROS generation or by modulating mitochondrial protein involved in apoptosis induction.
Keywords: Apoptosis, metabolism, oxidative stress, therapy, anti-tumoral therapy, cardiolipin, DNA fragmentation, Vitamin E, caspases, glycolysis
Current Pharmaceutical Design
Title: Mitochondrial Drug Targets in Cell Death and Cancer
Volume: 17 Issue: 20
Author(s): Gustavo Ferrin, Clara I. Linares and Jordi Muntane
Affiliation:
Keywords: Apoptosis, metabolism, oxidative stress, therapy, anti-tumoral therapy, cardiolipin, DNA fragmentation, Vitamin E, caspases, glycolysis
Abstract: Mitochondria are involved in different physiological and pathological processes that are crucial for tumor cell physiology, growth and survival. Since cancer cells have frequently disrupted different cell death pathways that promote their survival, mitochondria may be key organelles to promote cell death in cancer cells. The present review is focused on the different experimental and therapeutic cancer strategies addressed to either target mitochondria directly, or use mitochondria as mediators of apoptosis. While the first group includes drugs that act on glycolysis, β-oxidation, electron transport chain, mitochondrial permeability and the Bcl-2/IAP family protein, the second one consists of those drugs that cause cell death through the intrinsic apoptosis pathway by promoting ROS generation or by modulating mitochondrial protein involved in apoptosis induction.
Export Options
About this article
Cite this article as:
Ferrin Gustavo, I. Linares Clara and Muntane Jordi, Mitochondrial Drug Targets in Cell Death and Cancer, Current Pharmaceutical Design 2011; 17 (20) . https://dx.doi.org/10.2174/138161211796904803
DOI https://dx.doi.org/10.2174/138161211796904803 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Animal Peptides Targeting Voltage-Activated Sodium Channels
Current Pharmaceutical Design Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances
Current Drug Targets p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews Epoch-making Treatment with Transoral Robotic Surgery for Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Motor Unit and Neuromuscular Junction Remodeling with Aging
Current Aging Science Signaling Transduction Network Mediated by Tumor Suppressor/Susceptibility Genes in NPC
Current Genomics 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience
Current Radiopharmaceuticals Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Medicinal Perspective of Indole Derivatives: Recent Developments and Structure-Activity Relationship Studies
Current Drug Targets Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews Precise Analysis of the Autofluorescence Characteristics of Rat Colon Under UVA and Violet Light Excitation
Current Pharmaceutical Biotechnology Carrier Deformability in Drug Delivery
Current Pharmaceutical Design Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design